MIRACURE BIOTECHNOLOGY

MIRACURE BIOTECHNOLOGYMIRACURE BIOTECHNOLOGYMIRACURE BIOTECHNOLOGY
  • Home
  • Introduction
  • Pipelines
  • Technology
  • Contact Us
  • More
    • Home
    • Introduction
    • Pipelines
    • Technology
    • Contact Us

MIRACURE BIOTECHNOLOGY

MIRACURE BIOTECHNOLOGYMIRACURE BIOTECHNOLOGYMIRACURE BIOTECHNOLOGY
  • Home
  • Introduction
  • Pipelines
  • Technology
  • Contact Us

Next Generation Discovery Platform-Driven Biotech Company

About Us

Next Generation Discovery Platform-Driven Biotech Company

About Us

Welcome to Miracure Biotechnology

Miracure Biotechnology is a development stage biotech company committed to discover and develop novel small-molecule drug candidates and therapies for cancer, viral infections, and neurodegenerations.


Find out more

Pipelines

MCB017-Best in Class Broad Spectrum Oral Anti-viral Prodrug

MCB017-Best in Class Broad Spectrum Oral Anti-viral Prodrug

MCB017-Best in Class Broad Spectrum Oral Anti-viral Prodrug

  

  • Novel direct-acting antiviral nucleotide monophosphate prodrug specifically designed to target the viral RNA-dependent RNA polymerase (vRdRp);
  • Broadly active against many other ssRNA virus in the clinic with huge unmet medical needs as well as potential global health impact in pandemic;
  • Excellent oral PK in multiple           preclinical species and favorable tissue distribution, which translated into superior in vivo efficacy in COVID19 and RSV animal models.

MCB002 - Small Molecule Degrading p300/CBP

MCB017-Best in Class Broad Spectrum Oral Anti-viral Prodrug

MCB017-Best in Class Broad Spectrum Oral Anti-viral Prodrug

  

  • CBP/p300 are well known epigenetic targets for cancer therapy;
  • Small molecular inhibitors are in phase 2 for prostate cancer, multiple myeloma, AML et al. Inobrodib ( CCS1477) proved the safety for long term administration
  • Preclinical data from our compounds with degradation MoA demonstrated promising in vivo efficacy and favorable safety in 22RV1 model

TC006 - Small Molecules Targeting METTL3

MCB017-Best in Class Broad Spectrum Oral Anti-viral Prodrug

TC006 - Small Molecules Targeting METTL3

  • Identified novel METTL3 inhibtors with improved activities and profiles as an oral immune stimulator for immno-oncology applications against solid tumors

Next Generation XDC：Novel Payload Conjugation Technology

Peptide Drug Conjugate (PDC) with BRD4 Degrader

We use our in-house discovered small molecules with novel MoA other than the traditional chemotherapy as drug payload. PDC as  a platform to generate a new modality and pretest the payload for other conjugate form such as ADC to speed-up the development.

Small Molecule Drug Conjugate (SMDC) with TLR7/8 Agonist

Our SMDC deliver the proprietary immune-agonist to tumor-associated environment specifically to gain targeted immun-response and induce the tumor elimination with very limited side fact but elongated therapeutic effects.

Contact Us

Miracure Biotechnology

Beijing Site:

Bldg. No. 3 Unit B, Room 406

Dong Sheng International Science Park

No. 1 North Yong Tai Zhuang Road, Haidian District

Beijing, P.R. China


San Diego Site: 

6393 Nancy Ridge Drive, Ste B

San Diego, CA 92121

USA

Email:  info@miracurebio.com



Copyright © 2024 Miracure Biotechnology Inc. - All Rights Reserved.

Powered by GoDaddy

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept